LincoffAMBittlJAKleimanNS. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol.2004; 93: 1092–1096.
2.
LincoffAMBittlJAHarringtonRA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853–863.
3.
LinPHBushRLLubbeDF. Carotid artery stenting with routine cerebral protection in high-risk patients. Am J Surg.2004; 188: 644–652.
4.
LinPHBushRLLumsdenAB. Carotid artery stenting: Current status and future directions. Vasc Endovascular Surg.2003; 37: 315–322.
5.
ValensteinPNWalshMKMeierF. Heparin monitoring and patient safety: A College of American Pathologists Q-Probes study of 3431 patients at 140 institutions. Arch Pathol Lab Med.2004; 128: 397–402.
6.
KapadiaSRBajzerCTZiadaKM. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: A safe and effective adjunctive therapy. Stroke. 2001; 32: 2328–2332.
7.
QureshiAISaadMZaidatOO. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002; 33: 1916–1919.
